` AZN (AstraZeneca PLC) vs FTSE All Share Index Comparison - Alpha Spread

AZN
vs
F
FTSE All Share Index

Over the past 12 months, AZN has outperformed FTSE All Share Index, delivering a return of -15% compared to the FTSE All Share Index's 0% growth.

Stocks Performance
AZN vs FTSE All Share Index

Loading
AZN
FTSE All Share Index
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
AZN vs FTSE All Share Index

Loading
AZN
FTSE All Share Index
Difference
www.alphaspread.com

Performance By Year
AZN vs FTSE All Share Index

Loading
AZN
FTSE All Share Index
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
AstraZeneca PLC vs Peers

FTSE All Share Index
AZN
LLY
JNJ
NOVO B
ROG
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

AstraZeneca PLC
Glance View

AstraZeneca PLC stands as a formidable entity in the global pharmaceutical landscape, adeptly navigating the intricate dance of innovation and commerce. Emerging from a merger between Sweden's Astra AB and the UK's Zeneca Group in 1999, the company has carved a niche through its relentless pursuit of cutting-edge medical solutions. Central to its operations is a sophisticated ecosystem of research and development, where thousands of scientists tirelessly explore the expansive frontier of biotechnology. The lifeblood of AstraZeneca's growth is its robust pipeline, where potential life-saving medicines traverse an arduous journey from laboratory benches to clinical trials, and eventually, regulatory approval. This rigorous process underscores its commitment to addressing complex diseases in areas such as oncology, cardiovascular, and respiratory health – domains marked by high unmet medical needs and significant market demand. The commercial prowess of AstraZeneca is equally vital to its success narrative. With a global reach spanning over 100 countries, the company leverages its advanced production facilities and strategic partnerships to deliver its pharmaceutical breakthroughs to those in need. Revenue generation is predominantly through the sale of prescription drugs, with blockbuster medications serving as pivotal financial pillars. These products, once approved, are strategically marketed to healthcare providers, ensuring they gain traction in various markets. AstraZeneca's approach is finely tuned to balance the scale of mass production with the nuance of catering to specific regional demands, maintaining a competitive edge in a crowded pharmaceutical landscape. Through these intricacies of innovation, production, and strategic market positioning, AstraZeneca not only generates substantial revenues but also reinforces its mission to improve patient health outcomes worldwide.

AZN Intrinsic Value
14 794.82 GBX
Undervaluation 30%
Intrinsic Value
Price
Back to Top